Switch theme
Sign up to access all valuation multiples
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
2004
9.2K+
LTM Revenue $932M
LTM EBITDA $179M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hangzhou Tigermed has a last 12-month revenue of $932M and a last 12-month EBITDA of $179M.
In the most recent fiscal year, Hangzhou Tigermed achieved revenue of $910M and an EBITDA of $156M.
Hangzhou Tigermed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hangzhou Tigermed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.0B | $910M | XXX | XXX | XXX |
| Gross Profit | $387M | $392M | XXX | XXX | XXX |
| Gross Margin | 38% | 43% | XXX | XXX | XXX |
| EBITDA | $402M | $156M | XXX | XXX | XXX |
| EBITDA Margin | 39% | 17% | XXX | XXX | XXX |
| Net Profit | $276M | $279M | XXX | XXX | XXX |
| Net Margin | 27% | 31% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hangzhou Tigermed's stock price is CNY 42 (or $6).
Hangzhou Tigermed has current market cap of CNY 36.7B (or $5.1B), and EV of CNY 37.4B (or $5.2B).
See Hangzhou Tigermed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $5.1B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hangzhou Tigermed has market cap of $5.1B and EV of $5.2B.
Hangzhou Tigermed's trades at 5.5x LTM EV/Revenue multiple, and 28.9x LTM EBITDA.
Analysts estimate Hangzhou Tigermed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hangzhou Tigermed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.2B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 33.1x | XXX | XXX | XXX |
| P/E | 90.5x | XXX | XXX | XXX |
| P/E/Growth | 1.1x | XXX | XXX | XXX |
| EV/FCF | 50.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHangzhou Tigermed's NTM/LTM revenue growth is 9%
Hangzhou Tigermed's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $18K for the same period.
Over next 12 months, Hangzhou Tigermed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hangzhou Tigermed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hangzhou Tigermed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -61% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $18K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 18% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hangzhou Tigermed acquired XXX companies to date.
Last acquisition by Hangzhou Tigermed was XXXXXXXX, XXXXX XXXXX XXXXXX . Hangzhou Tigermed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hangzhou Tigermed founded? | Hangzhou Tigermed was founded in 2004. |
| Where is Hangzhou Tigermed headquartered? | Hangzhou Tigermed is headquartered in China. |
| How many employees does Hangzhou Tigermed have? | As of today, Hangzhou Tigermed has 9.2K+ employees. |
| Is Hangzhou Tigermed publicy listed? | Yes, Hangzhou Tigermed is a public company listed on SHE. |
| What is the stock symbol of Hangzhou Tigermed? | Hangzhou Tigermed trades under 300347 ticker. |
| When did Hangzhou Tigermed go public? | Hangzhou Tigermed went public in 2012. |
| Who are competitors of Hangzhou Tigermed? | Similar companies to Hangzhou Tigermed include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Hangzhou Tigermed? | Hangzhou Tigermed's current market cap is $5.1B |
| What is the current revenue of Hangzhou Tigermed? | Hangzhou Tigermed's last 12-month revenue is $932M. |
| What is the current EBITDA of Hangzhou Tigermed? | Hangzhou Tigermed's last 12-month EBITDA is $179M. |
| What is the current EV/Revenue multiple of Hangzhou Tigermed? | Current revenue multiple of Hangzhou Tigermed is 5.5x. |
| What is the current EV/EBITDA multiple of Hangzhou Tigermed? | Current EBITDA multiple of Hangzhou Tigermed is 28.9x. |
| What is the current revenue growth of Hangzhou Tigermed? | Hangzhou Tigermed revenue growth between 2023 and 2024 was -11%. |
| Is Hangzhou Tigermed profitable? | Yes, Hangzhou Tigermed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
